VXRT - Pendapatan operasional sadurunge ngurangi amortisasi vaxart.com

Vaxart, Inc. (VXRT) is developing innovative tablet-based vaccines for influenza and norovirus, leveraging support from BARDA and Phase 2 results. Monitoring EBITDA_Co allows for the tracking of actual cash flow, where serves as the final level marker. The business's success is based on patent protection and the confirmation of an immune response. The company is currently in the clinical testing stage, operating on grants.

VXRT - Bathi operasional sadurunge ngurangi amortisasi Vaxart Inc. ing rentang 04.07.2022 - 12.11.2026

Vaxart - rincian analitis lan metrik utama (VXRT)

- rega saham lan target rega konsensus:

Bagan rega Vaxart Inc.|VXRT - Prakiraan konsensus analis

- statistik kapitalisasi pasar:

Kapitalisasi pasar Vaxart|VXRT - Nilai Total Perusahaan

- data ekuitas miturut neraca:

Nilai Akuntansi Saham Vaxart|VXRT - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku vaxart.com|VXRT - Aset Agregat Perusahaan

- data tingkat utang lan likuiditas finansial:

- statistik bathi lan rasio pasar:

VXRT - Bathi resik perusahaan|Penghasilan resik sing dikarepake Vaxart, Inc.|VXRT - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep Vaxart Inc.|VXRT - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Vaxart|VXRT - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan Vaxart|VXRT - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan vaxart.com|VXRT - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Vaxart, Inc.

Ringkesan analitik perusahaan:VXRT (Vaxart, Inc.)

Absolute operating profit measures cash flow from core operations before depreciation and amortization, reflecting the business's ability to generate internal resources during periods of market volatility. This chart of operating profit before depreciation and amortization allows for an assessment of the financial model's resilience at Vaxart, Inc. (VXRT) amid the costly scaling of its oral vaccine platform and its dependence on government funding for clinical trials.

Analisis pesaing Vaxart, Inc.

Gilead Corp - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Cidara Therapeutics, Inc. - Bathi operasional EBITDA|Pendapatan operasional sadurunge ngurangi amortisasi novavax.com NVAX|CureVac (CVAC) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Valneva Corp - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi operasional sadurunge ngurangi amortisasi VIR|Bathi operasional EBITDA TPOXX|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Emergent BioSolutions (EBS)|Pendapatan operasional sadurunge ngurangi amortisasi ateapharma.com|Invivyd - Bathi operasional sadurunge ngurangi amortisasi|Enanta Pharmaceuticals Inc. - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Inovio Pharmaceuticals Inc - Bathi operasional EBITDA|HLVX - Bathi operasional EBITDA|KLRS (Kalaris Therapeutics Inc) - Bathi operasional sadurunge ngurangi amortisasi|Bathi operasional sadurunge amortisasi DYAI|NNVC (NanoViricides Inc.) - Bathi operasional EBITDA|Bathi operasional EBITDA Talphera Inc|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Cocrystal (COCP)|TRAW (trawspharma.com) - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Dogwood Therapeutics - Bathi operasional sadurunge ngurangi amortisasi|Bathi perusahaan sadurunge pajak, bunga, lan amortisasi QLGN (qualigeninc.com)|ALVR: Bathi operasional sadurunge ngurangi amortisasi|Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi VBIV (VBI Vaccines Inc.)|VIRI: Bathi operasional EBITDA